The collaboration integrates PICI’s RADIOHEAD real-world immunotherapy cohort into AMICA to optimize drug discovery and reduce clinical trial risk

Immunai, a leading AI biotech company specializing in mapping the human immune system, and the Parker Institute for Cancer Immunotherapy (PICI), a collaborative consortium of the world’s leading immuno-oncology experts, announced today that they will build the world’s largest single-cell dataset derived from a single cohort of patients treated with standard-of-care immunotherapy.

Under the collaboration with PICI, Immunai will perform single-cell RNA sequencing (scRNA-seq) and multi-omic profiling of patient blood samples collected from PICI’s RADIOHEAD (Resistance Drivers for Immuno-Oncology Patients Interrogated by Harmonized Molecular Datasets) cohort, a prospective longitudinal study of 1,070 patients receiving immune checkpoint inhibitor treatment regimens in a community setting.

Data generated from RADIOHEAD will be integrated into Immunai’s AMICA™ (Annotated Multi-omic Immune Cell Atlas) to support comparative analysis across diverse cancer types. The RADIOHEAD cohort is pan-cancer, including samples from patients with non-small cell lung cancer, small cell lung cancer, gastric cancer, hepatocellular carcinoma, melanoma, and others.

To support this effort, Immunai will leverage 10x Genomics’ Chromium GEM-X single-cell technology to accelerate this large-scale data generation. The combined dataset will help researchers in identifying biological patterns of immune response and resistance, enabling the study of clinically relevant mechanisms that may help guide future therapeutic strategies.

“PICI was built to support bold science that brings real benefit to patients,” said Tarak Mody, PhD, Chief Business Officer at PICI. “Our mission to turn all cancers into curable diseases starts with understanding why treatments work for some people and not for others.” Our collaboration with Immunai gives researchers a powerful resource to decode immune responses in real-world patients—and ultimately, to bring better immunotherapies to the people who need them most.”

“What’s truly exciting about this collaboration is that the RADIOHEAD cohort allows us to publicly showcase the kind of single-cell multi-omic profiling we typically sequence privately with biopharma and biotechnology companies,” said Noam Solomon, PhD, CEO and Co-Founder of Immunai. “The type of advanced AI we apply to such datasets provides a unique glimpse into the depth of insights our platform can offer—and generates a rich dataset that gives scientists and drug developers the power to spot the patient groups most likely to benefit from new treatments—and perhaps more importantly, where they might not.”

Source – The Parker Institute